RE: Psoriasis: Emerging Therateutic StrategiesTV you are usually trying to read between the lines . ha ha what a joke you are.
Try reading the bottom line..
Nature Reviews Drug Discovery 4, 19-34 (2005); doi:10.1038/nrd1607
Declaration of competing financial interests
Alice B. Gottlieb
Psoriasis: emerging therapeutic strategies. Nature Reviews Drug Discovery 4, 19-34 (2005); doi:10.1038/nrd1607
Declaration: A.B.G. receives research funding from Amgen Inc.; Biogen Idec, Inc.; Centocor, Inc.; Genentech, Inc; WH Conzen Chair in Clinical Pharmacology; Abbott Labs; Ligand Pharmaceuticals Inc.; Beiersdorf, Inc.; Fujisawa Healthcare, Inc.; Merck, Inc.; Celgene Corp.; and Novartis AG.
A.B.G.'s Speakers' Bureau Memberships include Amgen Inc.; Biogen Idec, Inc.; Wyeth Pharmaceuticals; Centocor, Inc.; and Schering-Plough Corp.
A.B.G. currently has consulting agreements with Amgen Inc.; Biogen Idec, Inc; CellGate, Inc; Centocor, Inc.; Genentech, Inc; Novartis AG; QUATRx Pharmaceuticals Co.; Wyeth Pharmaceuticals, Schering-Plough Corp.; Eisai; Celgene Corp.; Bristol Myers Squibb Co.; Beiersdorf, Inc., Warner Chilcott, Abbott Labs., Kemia, Sankyo